Skip to main content
Have a personal or library account? Click to login
Leveraging Social Determinants of Health to Enhance Recruitment of Underrepresented Populations in Clinical Trials Cover

Leveraging Social Determinants of Health to Enhance Recruitment of Underrepresented Populations in Clinical Trials

Open Access
|Nov 2024

References

  1. National Institutes of Health (Internet). Bethesda, MD: National Institutes of Health; c2024. NIH’s Definition of a Clinical Trial; updated 2024 June 10 [cited 2024 Jun 15]. Available from: https://grants.nih.gov/policy/clinical-trials/definition.htm
  2. Kelsey MD, Patrick-Lake B, Abdulai R, et al. Inclusion and diversity in clinical trials: Actionable steps to drive lasting change. Contemp Clin Trials. 2022 May;116:106740. doi: 10.1016/j.cct.2022.106740
  3. U.S. Food and Drug Administration [Internet]. Silver Spring, MD: U.S. Food and Drug Administration; c2024. Drug Trials Snapshots Summary Report; 2023; 2024 [cited 2024 Jun 1]. Available from: https://www.fda.gov/media/178602/download?attachment
  4. U.S. Census [Internet]. Washington, DC: U.S. Department of Commerce; c2024. Jensen E, Jones N, Rabe M, et al. 2020 U.S. population more racially and ethnically diverse than measured in 2010; updated 2023 Oct 11 [cited 2024 Jun 1]. Available from: https://www.census.gov/library/stories/2021/08/2020-united-states-population-more-racially-ethnically-diverse-than-2010.html
  5. Buffenstein I, Kaneakua B, Taylor E, et al. Demographic recruitment bias of adults in United States randomized clinical trials by disease categories between 2008 to 2019: A systematic review and meta-analysis. Sci Rep. 2023 Jan;13:42. doi: 10.1038/s41598-022-23664-1
  6. DeCormier Plosky W, Ne’eman A, Silverman BC, et al. Excluding people with disabilities from clinical research: Eligibility criteria lack clarity and justification. Health Aff (Millwood). 2022 Oct;41(10):1423-1432. doi: 10.1377/hlthaff.2022.00520
  7. Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR. Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA Intern Med. 2014 Nov;174(11):1868-70. doi: 10.1001/jamainternmed.2014.4758
  8. Sarraju A, Valencia A, Knowles JW, Maron DJ, Rodriguez F. Diverse Racial/Ethnic Group Underreporting and Underrepresentation in High-Impact Cholesterol Treatment Trials. Circulation. 2021 Jun 15;143(24):2409-2411. doi: 10.1161/CIRCULATIONAHA.120.050034
  9. National Academies [Internet]. Washington, DC: National Academies Press; c2024. National Academies of Sciences, Engineering, and Medicine. Bibbins-Domingo K, Helman A, editors. Improving representation in clinical trials and research: building research equity for women and underrepresented groups; 2022 [cited 2024 Sep 4]. Available from: https://nap.nationalacademies.org/catalog/26479/improving-representation-in-clinical-trials-and-research-building-research-equity
  10. Bodicoat DH, Routen AC, Willis A, et al. Promoting inclusion in clinical trials-a rapid review of the literature and recommendations for action. Trials. 2021 Dec 4;22(1):880. doi: 10.1186/s13063-021-05849-7
  11. Ehrhardt S, Appel LJ, Meinert CL. Trends in National Institutes of Health Funding for Clinical Trials Registered in ClinicalTrials.gov. JAMA. 2015 Dec 15;314(23):2566-7. doi: 10.1001/jama.2015.12206
  12. Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am. 2022 Jul;11:100252. doi: 10.1016/j.lana.2022.100252
  13. Unger JM, Hershman DL, Osarogiagbon RU, et al. Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. JNCI Cancer Spectr. 2020 Apr 24;4(4):pkaa034. doi: 10.1093/jncics/pkaa034
  14. Xiao H, Vaidya R, Liu F, Chang X, Xia X, Unger JM. Sex, Racial, and Ethnic Representation in COVID-19 Clinical Trials: A Systematic Review and Meta-analysis. JAMA Intern Med. 2023 Jan 1;183(1):50-60. doi: 10.1001/jamainternmed.2022.5600
  15. McDonald KE, Schwartz AE, Sabatello M. Eligibility criteria in NIH-funded clinical trials: Can adults with intellectual disability get in? Disabil Health J. 2022 Oct;15(4):101368. doi: 10.1016/j.dhjo.2022.101368
  16. Kanapuru B, Fernandes LL, Baines A, et al. Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials. Blood. 2023 Jul 20;142(3):235-243. doi: 10.1182/blood.2022018657
  17. Webb Hooper M, Asfar T, Unrod M, et al. Reasons for Exclusion from a Smoking Cessation Trial: An Analysis by Race/Ethnicity. Ethn Dis. 2019 Jan 17;29(1):23-30. doi: 10.18865/ed.29.1.23
  18. Guadagnolo BA, Petereit DG, Helbig P, et al. Involving American Indians and medically underserved rural populations in cancer clinical trials. Clin Trials. 2009 Dec;6(6):610-7. doi: 10.1177/1740774509348526
  19. Riner AN, Girma S, Vudatha V, et al. Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials. J Clin Oncol. 2022 Jul 10;40(20):2193-2202. doi: 10.1200/JCO.21.02492
  20. Defilippis EM, Echols M, Adamson PB, et al. Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory. JAMA Cardiol. 2022 May 1;7(5):540-548. doi: 10.1001/jamacardio.2022.0161
  21. Gupta DK, de Lemos JA, Ayers CR, Berry JD, Wang TJ. Racial Differences in Natriuretic Peptide Levels: The Dallas Heart Study. JACC Heart Fail. 2015 Jul;3(7):513-519. doi: 10.1016/j.jchf.2015.02.008
  22. Seidler EM, Keshaviah A, Brown C, Wood E, Granick L, Kimball AB. Geographic distribution of clinical trials may lead to inequities in access. Clin Invest. 2014;4:373-380. doi: 10.4155/cli.14.21
  23. Galsky MD, Stensland KD, McBride RB, et al. Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA Intern Med. 2015 Feb;175(2):293-5. doi: 10.1001/jamainternmed.2014.6300
  24. Agency for Healthcare Research & Quality [Internet]. Rockville, MD: US Department of Health and Human Services; c2024. National Healthcare Quality & Disparities Report; reviewed 2015 Jun [cited 2024 Sep 4]. Available from: http://www.ahrq.gov/research/findings/nhqrdr/nhqdr14/key1.html
  25. Tikkanen RS, Woolhandler S, Himmelstein DU, et al. Hospital Payer and Racial/Ethnic Mix at Private Academic Medical Centers in Boston and New York City. Int J Health Serv. 2017 Jul;47(3):460-476. doi: 10.1177/0020731416689549
  26. Occa A, Morgan SE, Potter JE. Underrepresentation of Hispanics and Other Minorities in Clinical Trials: Recruiters’ Perspectives. J Racial Ethn Health Disparities. 2018 Apr;5(2):322-332. doi: 10.1007/s40615-017-0373-x
  27. Giuliano AR, Mokuau N, Hughes C, et al. Participation of minorities in cancer research: the influence of structural, cultural, and linguistic factors. Ann Epidemiol. 2000 Nov;10(8 Suppl):S22-34. doi: 10.1016/s1047-2797(00)00195-2
  28. Versavel S, Subasinghe A, Johnson K, et al. Diversity, equity, and inclusion in clinical trials: A practical guide from the perspective of a trial sponsor. Contemp Clin Trials. 2023 Mar;126:107092. doi: 10.1016/j.cct.2023.107092
  29. BiopharmaDive [Internet]. Washington, DC: BiopharmaDive; c2024. Dunn A, Pagliarulo N. Follow the money: how biopharma CEOs and workers got paid in 2018; 2019 May 28 [cited 10 June 2024]. Available from https://www.biopharmadive.com/news/biotech-pharma-ceo-employee-pay/554283/
  30. Getz K, Faden L. Racial disparities among clinical research investigators. Am J Ther. 2008 Jan-Feb;15(1):3-11. doi: 10.1097/MJT.0b013e31815fa75a
  31. Reza N, Tahhan AS, Mahmud N. Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. Circ Heart Fail. 2020 Aug;13(8):e006605. doi: 10.1161/CIRCHEARTFAILURE.119.006605
  32. Yong C, Suvarna A, Harrington R, et al. Temporal Trends in Gender of Principal Investigators and Patients in Cardiovascular Clinical Trials. J Am Coll Cardiol. 2023 Jan 31;81(4):428-430. doi: 10.1016/j.jacc.2022.10.038
  33. Clark LT, Watkins L, Piña IL, et al. Increasing Diversity in Clinical Trials: Overcoming Critical Barriers. Curr Probl Cardiol. 2019 May;44(5):148-172. doi: 10.1016/j.cpcardiol.2018.11.002
  34. Millar MM, Taft T, Weir CR. Clinical trial recruitment in primary care: exploratory factor analysis of a questionnaire to measure barriers and facilitators to primary care providers’ involvement. BMC Prim Care. 2022 Dec 3;23(1):311. doi: 10.1186/s12875-022-01898-2
  35. Katz RV, Kegeles SS, Kressin NR, et al. Awareness of the Tuskegee Syphilis Study and the US presidential apology and their influence on minority participation in biomedical research. Am J Public Health. 2008 Jun;98(6):1137-42. doi: 10.2105/AJPH.2006.100131
  36. Wendler D, Kington R, Madans J, et al. Are racial and ethnic minorities less willing to participate in health research? PLoS Med. 2006 Feb;3(2):e19. doi: 10.1371/journal.pmed.0030019
  37. U.S. Department of Labor [Internet]. Washington, DC: U.S. Department of Labor; c2024. Earnings and Ratios: Women’s Bureau; 2024 [cited 2024 Sep 4]. Available from: https://www.dol.gov/agencies/wb/data/earnings
  38. Kaiser Family Foundation [Internet]. San Francisco, CA: Kaiser Family Foundation; c2024. Drake P, Burns A. Working-age adults with disabilities living in the community; 2024 Jan 4 [cited 2024 Sep 4]. Available from: https://www.kff.org/medicaid/issue-brief/working-age-adults-with-disabilities-living-in-the-community/
  39. Goodman JM, Richardson DM, Dow WH. Racial and Ethnic Inequities in Paid Family and Medical Leave: United States, 2011 and 2017–2018. Am J Public Health. 2022 Jul;112(7):1050-1058. doi: 10.2105/AJPH.2022.306825
  40. Bonevski B, Randell M, Paul C, et al. Reaching the hard-to-reach: a systematic review of strategies for improving health and medical research with socially disadvantaged groups. BMC Med Res Methodol. 2014 Mar 25;14:42. doi: 10.1186/1471-2288-14-42
  41. Friedman SH, Cunningham CO, Lin J, Haramati LB, Levsky JM. Having a Primary Care Provider is the Strongest Predictor of Successful Follow-up of Participants in a Clinical Trial. J Am Board Fam Med. 2020 May-Jun;33(3):431-439. doi: 10.3122/jabfm.2020.03.190018
  42. Gadegbeku CA, Stillman PK, Huffman MD, Jackson JS, Kusek JW, Jamerson KA. Factors associated with enrollment of African Americans into a clinical trial: results from the African American study of kidney disease and hypertension. Contemp Clin Trials. 2008 Nov;29(6):837-42. doi: 10.1016/j.cct.2008.06.001
  43. U.S. Food & Drug Administration [Internet]. Silver Spring, MD: U.S. Food & Drug Administration; c2024. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials; draft guidance for industry; 2022 Apr [cited 2024 Sep 4]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations
  44. National Institute of Health (Internet). Bethesda, MD: National Institute of Health; c2024. Diversity related funding opportunity announcements; 2024 [cited 2024 Sep 4]. Available from: https://extramural-diversity.nih.gov/guidedata/data
  45. Pfizer [Internet]. New York, NY: Pfizer; c2024. Covington. A report to Pfizer Inc. on its efforts to promote racial equity, diversity, and inclusion; 2024 May [cited 2024 Sep 4]. Available from: https://cdn.pfizer.com/pfizercom/Pfizer_Racial_Equity_Assessment_Report_031424.pdf
  46. Largent EA, Fernandez Lynch H. Paying Research Participants: Regulatory Uncertainty, Conceptual Confusion, and a Path Forward. Yale J Health Policy Law Ethics. 2017 Winter;17(1):61-141. PMID: 29249912
  47. Las Nueces D, Hacker K, Digirolamo A, Hicks LS. A systematic review of community-based participatory research to enhance clinical trials in racial and ethnic minority groups. Health Serv Res. 2012 Jun;47(3 Pt 2):1363-86. doi: 10.1111/j.1475-6773.2012.01386.x
  48. Crocker JC, Ricci-Cabello I, Parker A, et al. Impact of patient and public involvement on enrolment and retention in clinical trials: Systematic review and meta-analysis. BMJ. 2018 Nov 28;363:k4738. doi: 10.1136/bmj.k4738
  49. Centers for Disease Control and Prevention [Internet]. Atlanta, GA: Center for Disease Control and Prevention; c2024. Principles of Community Engagement. 2nd ed; 2011 Jun [cited 2024 Sep 4]. Available from: https://www.atsdr.cdc.gov/communityengagement/index.html
  50. Haynes N, Kaur A, Swain J, Joseph JJ, Brewer LC. Community-Based Participatory Research to Improve Cardiovascular Health Among US Racial and Ethnic Minority Groups. Curr Epidemiol Rep. 2022;9(3):212-221. doi: 10.1007/s40471-022-00298-5
  51. Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022 Apr;28(4):809-813. doi: 10.1038/s41591-022-01703-8
  52. Sarraju A, Seninger C, Parameswaran V, et al. Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP). NPJ Digit Med. 2022 Jun 28;5(1):80. doi: 10.1038/s41746-022-00622-9
  53. Kasahara A, Mitchell J, Yang J, Cuomo RE, McMann TJ, Mackey TK. Digital technologies used in clinical trial recruitment and enrollment including application to trial diversity and inclusion: A systematic review. Digit Health. 2024 Mar 28;10:20552076241242390. doi: 10.1177/20552076241242390
  54. Broadwin C, Azizi Z, Rodriguez F. Clinical Trial Technologies for Improving Equity and Inclusion in Cardiovascular Clinical Research. Cardiol Ther. 2023 Jun;12(2):215-225. doi: 10.1007/s40119-023-00311-y
  55. Blood AJ, Cannon CP, Gordon WJ, et al. Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network. JAMA Cardiol. 2023 Jan 1;8(1):12-21. doi: 10.1001/jamacardio.2022.4018. Erratum in: JAMA Cardiol. 2023 Jan 1;8(1):100. doi: 10.1001/jamacardio.2022.4695
  56. Brewer LC, Jenkins S, Hayes SN, et al. Community-based, cluster-randomized pilot trial of a cardiovascular mHealth intervention: Rationale, design, and baseline findings of the FAITH! Trial. Am Heart J. 2022 May;247:1-14. doi: 10.1016/j.ahj.2022.01.009
  57. Harrer S, Shah P, Antony B, Hu J. Artificial Intelligence for Clinical Trial Design. Trends Pharmacol Sci. 2019 Aug;40(8):577-591. doi: 10.1016/j.tips.2019.05.005
DOI: https://doi.org/10.14797/mdcvj.1447 | Journal eISSN: 1947-6108
Language: English
Page range: 81 - 88
Submitted on: Jul 11, 2024
Accepted on: Jul 22, 2024
Published on: Nov 5, 2024
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2024 Sara King, Sophia Trabanino, Zahra Azizi, Fatima Rodriguez, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.